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a  b  s  t  r  a  c  t
Transcatheter  aortic  valve  implantation  (TAVI)  has  rapidly  emerged  as a valid  therapeutic  option  for
patients  with  severe  symptomatic  aortic  stenosis  who  are  high  risk  or ineligible  for  conventional  surgical
aortic  valve  replacement.  Despite  its  minimally  invasive  nature,  TAVI  is  invariably  associated  with  com-vailable online 12 December 2013
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creening
plications  in  these  old  patients  that  may  affect  outcomes.  Although  the  success  of  TAVI  is  determined  by
multiple  factors,  good  screening  and  appropriate  patient  selection  is crucial.  Selection  of  the  right  patient
includes the determination  of risk  levels  and  feasibility  of  a  safe  procedure  in each  individual  case.  Here,
we describe  below  our  critical  appraisal  of patient  selection  for TAVI.
©  2013  Published  by  Elsevier  Ltd on  behalf  of  Japanese  College  of  Cardiology.eart team approach
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ntroduction
Transcatheter aortic valve implantation (TAVI) is now an estab-
ished treatment option for patients with severe symptomatic
ortic stenosis who are considered too high risk or ineligible for
urgical aortic valve replacement [1–3]. The Edwards SAPIEN trans-
atheter heart valve (THV; Edwards, Irvine, CA, USA) and Medtronic
oreValve (Medtronic, Minneapolis, MN,  USA) are available for
ommercial use in Europe and more than 80,000 patients have
lready undergone TAVI. Despite its minimally invasive nature,
the procedure for each individual patient. It is crucial that selection
of eligible patients be carried out by a team of experienced inter-
ventional cardiologists, cardiac surgeons, anesthetists, and imaging
specialists, deﬁned as the “Heart Team.”
Risk evaluation
TAVI is indicated for selected patients at high or prohibitive
surgical risk. Surgical risk has been quantiﬁed using the logisticAVI is invariably associated with complications that may  affect
utcomes. Appropriate patient selection includes the determina-
ion of risk levels and the assessment of the feasibility and safety of
∗ Corresponding author at: Department of Interventional Cardiology, Institut Hos-
italier Jacques Cartier, 6 avenue du Noyer Lambert, FR-91300 Massy, France.
el.:  +33 160134602; fax: +33 160134603.
E-mail address: t.lefevre@angio-icps.com (T. Lefèvre).
914-5087/$ – see front matter © 2013 Published by Elsevier Ltd on behalf of Japanese Co
ttp://dx.doi.org/10.1016/j.jjcc.2013.11.005European System for Cardiac Operative Risk Evaluation (Logistic
EuroScore) and the Society of Thoracic Surgeons (STS) Predicted
Risk Mortality score. However, a number of comorbid conditions
associated with adverse surgical outcomes are not included in these
risk calculation scores, including disabling arthritis, liver cirrho-
sis, porcelain aorta, chest radiation, dementia, recurrent pulmonary
emboli, right ventricular failure, cancer, cachexia, and frailty. Frailty
has been recently recognized as a signiﬁcant factor to be taken
into account when selecting patients for TAVI. Indeed, frailty is
llege of Cardiology.
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iig. 1. Frailty is associated with diminution of physical reserve which increases
ulnerability to stress.
onsidered to be a distinct clinical syndrome characterized by a
ecrease in muscle mass and energy expenditure as well as mal-
utrition, leading to extreme vulnerability to adverse events. In
ddition, the diminution of physical reserve associated with frailty
ncreases vulnerability to stress (Fig. 1) [4]. Although accurate
ssessment of frailty is difﬁcult to perform routinely, evaluation of
railty by geriatricians could be useful for patient selection. More-
ver, when there is doubt about the outcome after TAVI, balloon
ortic dilatation could prove to be a very good initial test before
lanning TAVI within 4 weeks after reassessment of the patient.
he European system for cardiac operative risk evaluation score II
ESII) was recently developed to improve the accuracy of the logis-
ic Euroscore. The ES II integrates partial quantiﬁcation of frailty
nto the model [5]. There are two studies showing that ES II has
etter predictive performance compared to logistic Euroscore and
TS, especially in transfemoral (TF) cohorts [6,7]. However, even
his model cannot adequately predict 30-day and 1-year mortality
fter TAVI. Additional studies are needed to create a new TAVI score
o further improve the identiﬁcation of the patients who would
eneﬁt from TAVI.
Renal function is reported to be associated with poor outcomes
fter TAVI. A recent report showed that chronic kidney disease
tage 4 before TAVI is associated with an increased risk of 30-day
nd 1-year mortality [8]. It has been observed that not only pre-
rocedural renal function but also post-procedural renal function
fter TAVI have an impact on the outcome. The results of other
ecently published analyses have demonstrated that acute kidney
njury (AKI), which is deﬁned as a post procedural decrease in renal
unction, is also associated with early and late mortality [9]. In
rder to prevent the occurrence of AKI, TAVI patients should receive
ptimal hydration, the total amount of contrast media should be
ig. 2. Vascular assessment using contrast angiography including the size, tortuosity, an
lio-femoral artery.iology 63 (2014) 178–181 179
minimized and the TF approach should be avoided in patients with
aortic debris in order to avoid distal embolization. The presence of
aortic debris can be easily assessed by transesophagal echocardi-
ography (TEE) or computed tomography scan and should be part of
the screening.
Coronary artery disease
Coronary artery disease (CAD) is a frequent comorbidity in
patients undergoing TAVI [10] and coronary angiogram is also part
of the screening process. We think that it should be performed
via the radial route in order to avoid utilizing the femoral arter-
ies before TAVI. Whether coronary revascularization should be
performed in TAVI candidates is still under debate as no random-
ized studies have yet addressed this subject. However, coronary
revascularization by means of percutaneous coronary intervention
seems reasonable in patients with signiﬁcant CAD, particularly in
the presence of proximal severe stenosis in major coronary arteries
[11]. Several issues, including completeness and timing of revas-
cularization in TAVI patients with CAD, remain open and further
studies are needed to clarify the management of CAD in TAVI can-
didates.
Vascular access screening
Selection of the vascular access site is a very important step
requiring careful pre-procedural screening. All patients are ini-
tially evaluated for transfemoral approach feasibility. Vascular
assessment is most commonly performed using selective iliac
angiography (Fig. 2) and multidetector computed tomography
(MDCT) (Fig. 3). The peripheral vasculature necessitates precise
assessment including the minimal vessel size, tortuosity, and cal-
ciﬁcation of the ilio-femoral arteries. The presence of aortic debris,
mobile plaques, excessive calciﬁcations, or extreme tortuosity of
the descending thoracic aorta should also be carefully assessed.
In such cases, it is important to discuss and assess alternative
approaches such as the trans-subclavian, trans-aortic, or trans-
apical routes.
Evaluation of the femoral access using selective contrast angiog-
raphy can be done during coronary angiogram. An SFAR ratio
>1.05 (outer Sheath diameter to Femoral Artery minimal luminal
diameter Ratio) has been identiﬁed as a predictor of major vas-
cular complications and 30-day mortality, as deﬁned by the Valve
Academic Research Consortium (VARC) [12]. MDCT is also recom-
mended for screening of the peripheral vasculature in potential
TAVI recipients [13], but we  should be careful to avoid accumu-
lation of contrast media in these patients with poor renal function.
d calciﬁcation of the ilio-femoral arteries: (a) right ilio-femoral artery and (b) left
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the risk of para-valvular leak. The optimal landing zone and skirt
F
aFig. 3. (a) and (b) Vascular assessment using multidetector computed tomo
nnulus assessment
Accurate measurement of the aortic annulus diameter is crucial
or appropriate valve sizing and for the outcomes of the procedure.
he aortic annulus is a complex 3-dimensional structure, and the
irtual ring has an oval shape formed by the junction of the nadirs
f all aortic valve leaﬂets at the distal part of the left ventricular out-
ow tract [14]. Overestimation of valve size can cause catastrophic
nnulus rupture, while underestimation may  result in valve migra-
ion or post-procedural paraprosthetic aortic regurgitation (AR).
R has been recognized as an independent predictor of long-term
ortality [15]. The two-year follow-up results of the PARTNER US
rial revealed that not only >3/4 AR, but also grade 2 AR had a sig-
iﬁcant impact on mortality [16]. Transthoracic echocardiography
TTE), and better TEE were used until recently to assess the annu-
us dimensions, but today MSCT is recognized as the gold standard
echnique of annulus size assessment. Many studies have shown
hat CT-guided valve sizing signiﬁcantly reduces the incidence of
ost-procedural AR compared to TEE [17]. Aortic annulus assess-
ent is easy to perform using MSCT because it is a 3-D acquisition
ith high spatial resolution in the 3 axes providing good evalu-
tion of the annulus and valve calciﬁcations. Simple rules should
e followed: measurements should be performed in systole at the
inge point attachment of the three aortic cusps, perpendicular to
he aortic root axis. In this plane, this virtual ring is usually oval in
hape with a long lateral axis and short antero-posterior axis. The
ntero-posterior axis is the axis measured by 2D echo. The annulus
urface can be traced manually and measured using the geometric
ean annulus diameter as mDiam-CT = 2
√
(annulus surface area/)
Fig. 4). The mean annulus diameter is in fact the mean value of all
ig. 4. Measurement of an aortic annulus on multidetector computed tomography: (a) t
nd  (b) mean-diameter was  calculated as mm based on the formula: mean Diam-CT = 2
√y including the size, tortuosity, and calciﬁcation of the ilio-femoral arteries.
diameters whatever the shape of the annulus. 3D TEE improves the
accuracy of annulus sizing but remains to date less accurate than
MSCT assessment.
Bioprosthesis type, size, and positioning
Two THV systems are currently available for implantation in
Europe. The Edwards SAPIEN XT THV is a balloon-expandable valve
that consists of a radiopaque cobalt chromium frame, trileaﬂet
bovine pericardial leaﬂets, and polyethylene terephthalate fabric
skirt. The Edwards SAPIEN XT THV can be implanted in native annuli
with diameters of 16 to 27 mm  (20, 23, 26, and 29 mm valve). The
optimal ratio between valve diameter and mean annulus diameter
as assessed by MSCT is 1.055. The Medtronic CoreValve biopros-
thesis is a self-expandable valve manufactured from a radiopaque
nitinol support frame, trileaﬂet porcine pericardial leaﬂets, and
porcine pericardium fabric skirt. The CoreValve can be implanted
in native annuli with diameters ranging from 17 to 29 mm (26, 29,
and 32 mm  valve). Because of the self-deployment nature of the
CoreValve, selection of the CoreValve diameter should be based on
the maximal annulus diameter rather than the mean diameter as
assessed by MSCT and the ratio should be >1.
Optimal positioning of the valve is crucial to avoid valve
embolization and coronary occlusion. In addition it also reducesheight for Edwards valve is summarized in Fig. 5 [18]. In CoreValve
recipients, if the aortic annulus plane is 12 mm higher than the
lower end of the metal frame, the gap between the annulus plane
and the skirt may  cause a severe paravalvular leak.
he short-axis and long-axis diameter were measured as mm and mm,  respectively
(annulus surface area/).
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[19] Nombela-Franco L, Rodes-Cabau J, DeLarochelliere R, Larose E, Doyle D,Fig. 5. Skirt height and optimal landing zone for Edw
ost dilatation
Optimal annulus sizing, and valve positioning, as well as post
ilatation when necessary, are instrumental in achieving device
mplantation success. Post dilatation is the ﬁrst option for the treat-
ent of signiﬁcant paravalvular leak after TAVI when the valve is
mplanted in the appropriate zone. After Edwards valve deploy-
ent, post dilatation with the same balloon which was used for
eployment with an additional 1–3 cc of contrast media has been
hown to be effective in reducing the grade of paravalvular leak
19]. However, excessive balloon oversizing may  lead to annulus
upture.
onclusions
TAVI has already become a mature technique which is inte-
rated into AS clinical paradigms. The heart team approach is
rucial for pre-procedural screening and management of pre- and
ost-procedural complications. Good screening contributes to at
east 50% of the ﬁnal result.
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